UK markets open in 7 hours 6 minutes
  • NIKKEI 225

    23,370.39
    -115.41 (-0.49%)
     
  • HANG SENG

    24,787.19
    -131.59 (-0.53%)
     
  • CRUDE OIL

    38.98
    -0.59 (-1.49%)
     
  • GOLD FUTURES

    1,907.90
    -4.00 (-0.21%)
     
  • DOW

    27,463.19
    -222.19 (-0.80%)
     
  • BTC-GBP

    10,538.12
    +34.01 (+0.32%)
     
  • CMC Crypto 200

    271.84
    +10.55 (+4.04%)
     
  • ^IXIC

    11,431.35
    +72.41 (+0.64%)
     
  • ^FTAS

    3,233.99
    -37.09 (-1.13%)
     

Global Severe Acute Respiratory Syndrome (SARS) Pipeline Review 2020: Therapeutic Analysis of 26 Companies & Drug Profiles

Research and Markets
·4-min read

Dublin, Oct. 01, 2020 (GLOBE NEWSWIRE) -- The "Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 1, 13 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:

Introduction

  • Severe Acute Respiratory Syndrome (SARS) - Overview

  • Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment

Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development

  • Severe Acute Respiratory Syndrome (SARS) - Drug Profiles

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects

  • Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones

Appendix

Companies Mentioned

  • Adagio Therapeutics Inc

  • AIkido Pharma Inc

  • AIM ImmunoTech Inc

  • Autoimmune Technologies LLC

  • Biotron Ltd

  • CEL-SCI Corp

  • Citospin SL

  • Cocrystal Pharma Inc

  • Fab'entech SA

  • Gilead Sciences Inc

  • Global BioLife Inc Ltd

  • Immodulon Therapeutics Ltd

  • Lattice Biologics Ltd

  • Merck & Co Inc

  • Novartis AG

  • Novavax Inc

  • Oncovir Inc

  • Organicell Regenerative Medicine Inc

  • Pharmazz Inc

  • Phelix Therapeutics LLC

  • Pulmotect Inc

  • Sagimet Biosciences

  • Sorrento Therapeutics Inc

  • Theravectys SA

  • Trimunocor Ltd

  • VBI Vaccines Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/j0rx1g

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900